New precision approach aims to wipe out breast cancer before surgery

NCT ID NCT05582499

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. About 716 participants with operable breast cancer will receive tailored neoadjuvant therapy, with follow-up to assess long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalpiciclib, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-A1921, Pertuzumab, Trastuzumab, Goserelin
What this could lead to: If successful, this could identify more effective drug combinations tailored to specific breast cancer subtypes, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong: This is a Phase 2 single-center trial, so results may not apply broadly. The many drug combinations increase complexity and risk of side effects, and not all may prove effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Her2-receptor negative breast cancer hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASM BREAST TUMORS EARLY-STAGE BREAST CANCER HER2-NEGATIVE BREAST CANCER HER2-POSITIVE BREAST CANCER HORMONE RECEPTOR NEGATIVE TUMOR HORMONE RECEPTOR POSITIVE TUMOR LOCALLY ADVANCED BREAST CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Fudan University Shanghai Cancer Center Shanghai, China, 200032
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.